Evidence map›Paper›PMID 30085955›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2018

Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System.

Matthew A Spinelli, Hyman M Scott, Eric Vittinghoff, Albert Y Liu, Alicia Morehead-Gee, Rafael Gonzalez, Monica Gandhi, Susan P Buchbinder

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. MTrials · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Matthew A SpinelliDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, CA.
Hyman M ScottDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, CA.
Eric Vittinghoff
Albert Y LiuBridge HIV, San Francisco Department of Public Health, San Francisco, CA.
Alicia Morehead-GeeMedicine, University of California, San Francisco, San Francisco, CA.
Rafael GonzalezBridge HIV, San Francisco Department of Public Health, San Francisco, CA.
Monica GandhiDivision of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, CA.
Susan P BuchbinderBridge HIV, San Francisco Department of Public Health, San Francisco, CA.
University of California, San Francisco · USCancer Research And Biostatistics · USSan Francisco Department of Public Health · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherenceR01MH109320 · NIMH · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI BUCHBINDER, SUSAN · 2015 to 2018
$3.9M
NIAID NIH HHS P30 AI027763NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI069496NIMH NIH HHS R01 MH109320
6 · The paper itself

Abstract

backgroundTimely pre-exposure prophylaxis (PrEP) initiation is critical in at-risk populations, given that HIV acquisition risk persists during delays. Time to treatment initiation, a key metric in HIV care, has not been explored among PrEP users. Interventions that reduce time to PrEP initiation could prevent HIV infections.

settingIndividuals initiating PrEP in a large primary care health network of 15 clinics, the San Francisco Primary Care Clinics (SFPCC), from July 2012 to July 2017 (N = 411).

methodsWe examined factors associated with time from first PrEP discussion with a provider to PrEP initiation date using an adjusted Cox proportional-hazards model, with hazard ratios (HRs) >1 indicating earlier initiation. We also examined the relationship between delayed PrEP initiation and PrEP persistence (staying on PrEP) in an adjusted Cox proportional-hazards model.

resultsPrEP users initiated PrEP after a median of only 7 days. However, there were notable outliers, with 29% waiting >30 days and 12% waiting >90 days. In an adjusted proportional-hazards model, a panel management and patient navigation intervention was associated with earlier PrEP initiation [HR: 1.5; 95% confidence interval (CI): 1.1 to 2.0], whereas only other race/ethnicity compared with white race was associated with delayed PrEP initiation (HR: 0.7; 95% CI: 0.5 to 1.0). Delayed PrEP initiation >30 days was associated with shorter PrEP persistence in an adjusted proportional-hazards model (HR: 1.3; 95% CI: 1.0 to 1.7).

conclusionsPrEP initiation within a week is feasible in a primary care safety-net health system. Setting a goal of rapid PrEP initiation, with the support of panel management and patient navigation, could address delays in at-risk groups.

Indexed as

AdultAnti-HIV AgentsChemopreventionDisease Transmission, InfectiousDrug UtilizationFemaleHIV InfectionsHumansMaleMiddle AgedPatient NavigationPre-Exposure ProphylaxisPrimary Health CareSan FranciscoAnti-HIV Agents

Identifiers

PMID30085955
PMCPMC6185763
OpenAlexW2887701756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.